Bristol-Myers Squibb: In the Pipeline
 
In the Pipeline
As of February 15, 2013

Bristol-Myers Squibb's pipeline is one of the most innovative in the industry.
Learn more about the medicines we are developing.


Exploratory Development
(Post discovery through Phase II)
Full Development
(Registrational program)
Marketed Product Development
(Approved in at least one major market)
Anti-Fucosyl GM1 (oncology) Nivolumab (Anti-PD1)
(oncology)
YERVOY® (ipilimumab) (oncology)
JAK2 Inhibitor (oncology) Elotuzumab
(oncology)
SPRYCEL® (dasatinib) (oncology)
IL-21 (oncology) Metreleptin
(metabolics)
ERBITUX® (cetuximab) (oncology)
Lirilumab (Anti-KIR) (oncology) Daclatasvir (NS5A inhibitor)
(virology)
FORXIGA™** (dapagliflozin) (metabolics)
Urelumab (Anti-CD137) (oncology) Asunaprevir (NS3 inhibitor)
(virology)
ONGLYZA® (saxagliptin)
KOMBIGLYZE XR™ (saxagliptin and metformin HCL extended-release)
(metabolics)
Notch Inhibitors (oncology) Peginterferon lambda-1a
(virology)
SYMLIN® (pramlintide acetate) injection (metabolics)
Anti-CXCR4 (oncology) BYETTA® (exenatide) injection(metabolics)
BYDUREON® (exenatide extended-release for injectable suspension)
(metabolics)
Anti-LAG3 (oncology) ORENCIA® (abatacept)
(immunology)
GPR119 Agonist
(metabolics)
NULOJIX® (belatacept) (immunology)
PEG-FGF21 (metabolics) ELIQUIS® (apixaban)
(cardiovascular)
11βHSD Inhibitor (metabolics) BARACLUDE® (entecavir)
(virology)
GPR40 Agonist (metabolics) REYATAZ® (atazanavir sulfate) (virology)
Anti-CD40L (immunology) SUSTIVA® (efavirenz)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
(virology)
Anti-CD40 (immunology)
**FORXIGA is not approved in the U.S.
Anti-CD28 (immunology)
Anti-IL31 (immunology)
Anti-IP10 (immunology)
IL-17/IL-23 biAb (immunology)
S1P1 Modulator (immunology)
LPA1 Antagonist (immunology)
CCR1 Antagonists (immunology)
Clazakizumab (Anti-IL6) (immunology)
LXR Modulators (cardiovascular)
PCSK9 Adnectin (cardiovascular)
CCR2 / 5 Antagonists (cardiovascular)
IKur Antagonists (cardiovascular)
Factor XIa Inhibitor (Parenteral) (cardiovascular)
Factor XIa Inhibitor (Oral) (cardiovascular)
PEG-Relaxin (cardiovascular)
HIV Attachment Inhibitor (virology)
NRT Inhibitor (virology)
HIV Maturation Inhibitor (virology)
Anti-PD-L1 (virology)
NS5B Non Nuc (virology)
α-7 Nicotinic Agonist (neuroscience)
Gamma Secretase Modulator (neuroscience)
Triple Reuptake Inhibitor (neuroscience)
Microtubule Stabilizer (neuroscience)
Myostatin Adnectin (neuroscience)
Please click on product name to see the Full U.S. Prescribing Information for ATRIPLA®, BARACLUDE®, BYDUREON®, BYETTA®, ELIQUIS®, ERBITUX®, KOMBIGLYZE™ XR, NULOJIX®, ONGLYZA®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, SYMLIN®, YERVOY®, including boxed WARNINGS for ATRIPLA®, BARACLUDE®, BYDUREON®, ELIQUIS®, NULOJIX®, and SYMLIN®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

Exploratory Development compounds are investigational drugs that are post discovery through Phase II.

Full Development compounds are investigational drugs that are in late-stage clinical development, or have been submitted to regulatory agencies for approval.

Marketed Product Development compounds have been approved in at least one major market and are among approved medicines that are under further study to determine the safety and efficacy of potential additional indications and formulations.



Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.